Switching from Vyvanse 70mg to Desoxyn: Direct Conversion Protocol
There is no established guideline or FDA-approved protocol for switching from lisdexamfetamine (Vyvanse) to methamphetamine (Desoxyn), and this conversion should only be undertaken in exceptional circumstances with extreme caution due to Desoxyn's high abuse potential and lack of evidence supporting this specific switch.
Critical Context
The evidence provided contains no guidelines or research addressing this specific medication switch. The available ADHD treatment guidelines 1, 2, 3 discuss stimulant selection and switching between methylphenidate and amphetamine families, but Desoxyn (methamphetamine) is conspicuously absent from all modern ADHD treatment algorithms. This absence is deliberate—methamphetamine is rarely used in contemporary ADHD management due to superior alternatives with lower abuse liability.
Why This Switch Is Problematic
Pharmacological Considerations
Vyvanse 70mg is a prodrug that converts to dextroamphetamine after ingestion, providing approximately 30mg of active dextroamphetamine over an extended release period 4. Desoxyn contains methamphetamine, which is pharmacologically distinct with:
- Higher CNS penetration than dextroamphetamine
- Greater dopaminergic effects
- Significantly higher abuse potential
- No extended-release formulation available
Regulatory and Clinical Reality
Research on lisdexamfetamine focuses on its lower abuse potential compared to immediate-release stimulants 1. Studies specifically highlight that lisdexamfetamine's prodrug design makes it "only activated after ingestion, when it is metabolized by erythrocyte cells to dexamphetamine," making "extraction of the stimulant medication more difficult" 1. This is the opposite direction from switching to Desoxyn.
If This Switch Must Occur
Step 1: Establish Medical Necessity
Document why all standard alternatives have failed:
- Inadequate response to both methylphenidate AND amphetamine families at therapeutic doses
- Trials of immediate-release dextroamphetamine or mixed amphetamine salts
- Assessment for substance use disorder (current or history)—Desoxyn is contraindicated if positive
- Evaluation for diversion risk factors 1
Step 2: Dose Conversion Estimate
Using general stimulant equivalency principles (though not validated for this specific conversion):
- Vyvanse 70mg ≈ 30mg dextroamphetamine
- Methamphetamine is approximately twice as potent as dextroamphetamine
- Initial Desoxyn dose: 10-15mg daily in divided doses (5mg twice daily)
- Maximum FDA-approved dose: 25mg/day in divided doses
Step 3: Transition Method
Abrupt switch with dose reduction (not cross-titration):
- Stop Vyvanse on Day 0
- Start Desoxyn 5mg twice daily (morning and early afternoon) on Day 1
- Monitor for 1 week before any dose adjustment
- Titrate by 5mg increments weekly if needed, maximum 25mg/day total
Rationale: No extended-release Desoxyn formulation exists, requiring multiple daily doses. Starting lower accounts for methamphetamine's greater potency and abuse potential.
Step 4: Intensive Monitoring
- Weekly visits for first month
- Urine drug screening at each visit
- Blood pressure and heart rate at each visit
- Assessment for signs of misuse, diversion, or dose escalation
- Prescription monitoring program review
- Consider prescribing only 1-week supplies initially
Critical Warnings
Desoxyn carries extreme risks:
- Schedule II controlled substance with highest abuse potential among ADHD medications
- Cardiovascular risks including sudden death, myocardial infarction, stroke 5
- Psychiatric adverse effects including psychosis, mania, aggression
- No evidence supporting superiority over other amphetamines for ADHD
Alternative approaches to consider first:
- Immediate-release dextroamphetamine (Dexedrine) 10-15mg divided doses
- Mixed amphetamine salts immediate-release (Adderall) 15-20mg divided doses
- Combination of long-acting stimulant with immediate-release booster
- Addition of non-stimulant (atomoxetine, guanfacine) to current regimen 3
Documentation Requirements
Document in medical record:
- Specific reasons all standard treatments failed
- Discussion of risks including abuse, diversion, cardiovascular events
- Patient/family understanding and agreement
- Plan for intensive monitoring
- Consultation with addiction medicine or psychiatry specialist
This conversion represents an extreme outlier in modern ADHD pharmacotherapy and should prompt reconsideration of the diagnosis, comorbidities, and treatment approach rather than proceeding with Desoxyn in most cases.